WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, February 02, 2006

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR		
☐	L6	((514/9 and lyoph$ and L4))!	111
☐	L5	lyoph$ and L4	7609
☐	L4	(peptide or protein or polypeptide or amino adj acid) and L3	16992
☐	L3	cyclic and L2	19842
☐	L2	fung$ and (lactose or maltose or sucrose or disaccharide or polysaccharide or sodium adj chloride)	65383
	DB=USPT; PLUR=YES; OP=OR		
☐	L1	6774104.pn.	1

END OF SEARCH HISTORY

C:\Program Files\Stnexp\Queries\10772281sub1.str





chain nodes :
1 19 20 21 22 23 24
ring nodes :
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
1-4 1-23 1-24 7-8 10-14 17-19 19-20 20-21 21-22
ring bonds :
2-3 2-7 3-4 4-5 5-6 6-7 8-9 8-11 9-10 10-12 11-12 13-14 13-18 14-15 15-16
16-17 17-18
exact/norm bonds :
1-23 1-24 8-9 8-11 9-10 10-12 11-12 17-19 19-20
exact bonds :
1-4 7-8 10-14 20-21 21-22
normalized bonds :
2-3 2-7 3-4 4-5 5-6 6-7 13-14 13-18 14-15 15-16 16-17 17-18

Match level :
1:CLASS 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS

C:\Program Files\Stnexp\Queries\10772281.str





chain nodes :
1 19 20 21 22 23 24 25 26 27 28 29 30 31 32
ring nodes :
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
1-4 1-30 1-31 7-8 10-14 17-19 19-20 20-21 20-23 20-24 21-22 21-25 21-26
22-29 22-27 22-28 31-32
ring bonds :
2-3 2-7 3-4 4-5 5-6 6-7 8-9 8-11 9-10 10-12 11-12 13-14 13-18 14-15 15-16
16-17 17-18
exact/norm bonds :
1-30 1-31 8-9 8-11 9-10 10-12 11-12 17-19 19-20
exact bonds :
1-4 7-8 10-14 20-21 20-23 20-24 21-22 21-25 21-26 22-29 22-27 22-28 31-32
normalized bonds :
2-3 2-7 3-4 4-5 5-6 6-7 13-14 13-18 14-15 15-16 16-17 17-18

Match level :
1:CLASS 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS

L7 73 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Deoxymulundocandin, 1-[(4R)-4-[[(1R,2R)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]- (9CI)
SQL 6
MF C60 H80 N10 O15
CI COM

RELATED SEQUENCES AVAILABLE WITH SEQLINK

PAGE 1-A



PAGE 2-A




R
CH—Me
OH

L7 73 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pneumocandin A0, 1-[(4R)-4-hydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]- (9CI)
SQL 6
MF C56 H71 N9 O21 S
CI COM

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 73 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Echinocandin B, 1-[(4R)-4-hydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[4-[4-hydroxy-3-(sulfooxy)phenyl]-L-

threonine]-5-[(3R)-3-hydroxy-L-ornithine]- (9CI)
SQL 6
MF C56 H73 N9 O20 S

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 73 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Echinocandin B, 1-[(4R)-N2-[4-[5-[4-[[7-[(2R,6S)-2,6-dimethyl-4-morpholinyl]heptyl]oxy]phenyl]-3-isoxazolyl]benzoyl]-4-hydroxy-L-ornithine]-4-[4-[4-[[(2-propenyloxy)carbonyl]oxy]-3-(sulfooxy)phenyl]-L-threonine]-5-[(3R)-3-hydroxy-N5-[2-hydroxy-1-(hydroxymethyl)ethyl]-N5-[(2-propenyloxy)carbonyl]-L-ornithine]- (9CI)
MF C75 H102 N10 O27 S
CI COM

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




Me
N
S
R
O
Me

(FILE 'HOME' ENTERED AT 23:07:18 ON 02 FEB 2006)

FILE 'REGISTRY' ENTERED AT 23:07:27 ON 02 FEB 2006

L1 STRUCTURE UPLOADED
L2 0 S L1 FAM SAM
L3 0 S L1 FAM FULL
L4 STRUCTURE UPLOADED
L5 0 S L4 FAM SAM
L6 3 S L4 SSS SAM
L7 73 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 23:19:29 ON 02 FEB 2006

L8 157 S L7
L9 157446 S L8 AND LACTOSE OR SUCROSE OR MALTOSE
L10 4 S L8 AND (LACTOSE OR SUCROSE OR MALTOSE)
L11 140 S L8 AND (FUNGAL OR FUNGUS OR FUNG?)
L12 0 S L11 AND LYOPH?
L13 2 S L11 AND (POLYSACCHARID? OR DISACCHARID? OR SODIUM CHLORIDE)

```
     (FILE 'HOME' ENTERED AT 23:07:18 ON 02 FEB 2006)

     FILE 'REGISTRY' ENTERED AT 23:07:27 ON 02 FEB 2006
L1             STRUCTURE UPLOADED
L2           0 S L1 FAM SAM
L3           0 S L1 FAM FULL
L4             STRUCTURE UPLOADED
L5           0 S L4 FAM SAM
L6           3 S L4 SSS SAM
L7          73 S L4 SSS FULL

     FILE 'CAPLUS' ENTERED AT 23:19:29 ON 02 FEB 2006

=> s l7
L8         157 L7

=> s l8 and lactose or sucrose or maltose
         49217 LACTOSE
            93 LACTOSES
         49225 LACTOSE
                 (LACTOSE OR LACTOSES)
        139861 SUCROSE
            92 SUCROSES
        139872 SUCROSE
                 (SUCROSE OR SUCROSES)
         26661 MALTOSE
            40 MALTOSES
         26667 MALTOSE
                 (MALTOSE OR MALTOSES)
L9      157446 L8 AND LACTOSE OR SUCROSE OR MALTOSE

=> s l8 and (lactose or sucrose or maltose)
         49217 LACTOSE
            93 LACTOSES
         49225 LACTOSE
                 (LACTOSE OR LACTOSES)
        139861 SUCROSE
            92 SUCROSES
        139872 SUCROSE
                 (SUCROSE OR SUCROSES)
         26661 MALTOSE
            40 MALTOSES
         26667 MALTOSE
                 (MALTOSE OR MALTOSES)
L10          4 L8 AND (LACTOSE OR SUCROSE OR MALTOSE)

=> d l10 1-4 bib abs

L10  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2005:612064  CAPLUS
DN   143:139157
TI   Preparation of rigid liposomal cochleate
IN   Krause-Elsmore, Sara L.; Mannino, Raphael J.
PA   Biodelivery Sciences International, Inc., USA
SO   PCT Int. Appl., 50 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2005063213        A1    20050714    WO 2004-US42927        20041220
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
```

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-531546P P 20031219
US 2004-565120P P 20040423

AB Employing liposomes having a high transition temperature at least partially disposed in a matrix, compns. are provided that can be used to deliver one or more cargo moieties, e.g., a drug, a nutrient, an imaging agent and/or nonsteroidal anti-inflammatory drug. The matrix can be a lipid precipitate and/or a cationic bridge. Methods of making and using these compns. preferably cochleates, are also disclosed. Rigid liposomes were obtained from distearoylphosphatidylserine and dextran.

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:902155 CAPLUS
DN 141:384286
TI Novel encochleation methods, cochleates and methods of use
IN Mannino, Raphael J.; Gould-Fogerite, Susan; Krause-Elsmore, Sara L.; Delmarre, David; Lu, Ruying
PA Biodelivery Sciences International, Inc., USA; University of Medicine and Dentistry of New Jersey
SO PCT Int. Appl., 195 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091578	A2	20041028	WO 2004-US11026	20040409
WO 2004091578	C1	20050127		
WO 2004091578	A3	20050331		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005013854	A1	20050120	US 2004-822230	20040409

PRAI US 2003-461483P P 20030409
US 2003-463076P P 20030415
US 2003-499247P P 20030828
US 2003-502557P P 20030911
US 2003-532755P P 20031224
US 2004-537252P P 20040115
US 2004-556192P P 20040324

AB The invention generally relates to cochleate drug delivery vehicles. Disclose are novel methods for making cochleates and cochleate compns. that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compns. that include an aggregation inhibitor, and optionally, a cargo moiety. Addnl., anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a neg. charge lipid are disclosed. Methods of using the cochleate compns. of the invention, including methods of administration, are also disclosed.

L10 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:757023 CAPLUS
DN 139:281230

TI Bioadhesive vaginal drug delivery system containing an acidic buffer
IN Kirschner, Mitchell I.; Levinson, R. Saul; Riley, Thomas C.; Hermelin, Marc S.
PA KV Pharmaceutical Company, USA
SO U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003180366	A1	20030925	US 2002-101014	20020320
US 6899890	B2	20050531		
CA 2392473	AA	20030920	CA 2002-2392473	20020628
BR 2002002767	A	20040525	BR 2002-2767	20020718
CN 1444926	A	20031001	CN 2002-127087	20020729
JP 2003286193	A2	20031007	JP 2002-266381	20020912
PT 102854	A	20030930	PT 2002-102854	20021015
PT 102854	B	20040227		
FR 2837389	A1	20030926	FR 2002-14858	20021127
WO 2003079981	A2	20031002	WO 2003-US8266	20030319

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-101014 A 20020320
AB The present invention relates to a novel essentially pH neutral vaginal drug delivery system suitable for modified delivery of a therapeutically active material in the vaginal cavity. The vaginal drug delivery system comprises an essentially pH neutral emulsion having globules having two phases, an internal water soluble phase and an external water-insol. phase or film, wherein the water-soluble interior phase contains a therapeutically active drug or drugs. One novel aspect of the vaginal drug delivery system is that the internal water soluble phase comprises an acidic buffered phase. For example, a vaginal drug delivery system was prepared containing metronidazole 0.75%, water 24.676%, glycerin 47.25%, acetic acid 0.225%, sodium acetate 0.20%, sodium chloride 0.75%, methylparaben 0.09%, propylparaben 0.035%, butylparaben 0.024%, **sucrose** 8.0%, mineral oil 13.0%, and polyethylene glycol (30) dipolyhydroxystearate 5.0%.
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:31345 CAPLUS
DN 134:105851
TI Stabilized cyclic polypeptide pharmaceutical composition in lyophilized form
IN Sawai, Seiji; Kasai, Akihiro; Otomo, Kazumi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001002002	A1	20010111	WO 2000-JP4381	20000629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,

ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA	2341568	AA	20010111	CA 2000-2341568	20000629
AU	2000055722	A5	20010122	AU 2000-55722	20000629
AU	752265	B2	20020912		
BR	2000006823	A	20010605	BR 2000-6823	20000629
EP	1107777	A1	20010620	EP 2000-940916	20000629
EP	1107777	B1	20041027		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, LT, LV, FI, RO

TR	200100609	T1	20010723	TR 2001-200100609	20000629
JP	2002363097	A2	20021218	JP 2001-312701	20000629
JP	2003503462	T2	20030128	JP 2001-507492	20000629
JP	3381722	B2	20030304		
NZ	510290	A	20030725	NZ 2000-510290	20000629
AT	280583	E	20041115	AT 2000-940916	20000629
PT	1107777	T	20050131	PT 2000-940916	20000629
ES	2225161	T3	20050316	ES 2000-940916	20000629
RU	2251411	C2	20050510	RU 2001-108569	20000629
CZ	295720	B6	20051012	CZ 2001-1186	20000629
NO	2001000893	A	20010424	NO 2001-893	20010222
ZA	2001001589	A	20020902	ZA 2001-1589	20010226
US	6774104	B1	20040810	US 2001-786125	20010301
HK	1040057	A1	20050805	HK 2002-101689	20020305
US	2004157769	A1	20040812	US 2004-772281	20040206

PRAI	JP 1999-187713	A	19990701
	JP 2001-507492	A3	20000629
	WO 2000-JP4381	W	20000629
	US 2001-786125	A3	20010301

OS MARPAT 134:105851

AB A stabilized pharmaceutical composition in lyophilized form comprises a cyclic polypeptide and one or more stabilizer(s) selected from the group consisting of a polysaccharide, a disaccharide and sodium chloride. A composition was prepared containing a cyclic polypeptide and **lactose**.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT